# Anti-Human CD13 (WM15)













FITC 13F2-100T PΕ

100 test 13PE2-100T 100 test

20 µg/test 20 µg/test



### 1. PRODUCT DESCRIPTION

Clone: WM15:

Isotype: IgG1;

Tested application: flow cytometry;

Immunogen: The anti-CDI3 monoclonal antibody derives from leucocytes cells;

Species reactivity: Human. Cross-Reactivity: Chimpanzee, Baboon, Cotton-topped Tamarin:

Storage instruction: store in the dark at 2-8 °C;

Storage buffer: aqueous buffered solution containing protein stabilizer and 0.09% sodium azide (NaN<sub>2</sub>);

Recommended usage: Immunostep's CD13, clone WM15, is a monoclonal antibody intended for the identification and enumeration of human leucocytes using flow cytometry. This reagent is effective for direct immunofluorescence staining of human tissue for flow cytometric analysis using 1 test for 106 cells;

Presentation: liquid;

**Source**: Supernatant proceeding from an in vitro cell culture of a cell hybridoma:

Purification: Affinity chromatography;

Other names: Aminopeptidase N, Alanyl aminopeptidase, Aminopeptidase M, Microsomal aminopeptidase, Myeloid plasma membrane glycoprotein CD13, gp150;

Molecular weight: 109,54 kDa.

### 2. ANTIGEN DETAILS

Large description: The monoclonal antibody is directed against the CDI3-antigen, which is expressed on human monocytes, granulocytes and their precursors and a small population of large granular lymphocytes. The monoclonal antibody reacts with monocytes, granulocytes and with a large number of acute myeloid leukaemia's (the positivity of this marker relates to worse clinic prognosis).(1-6)

### WARRANTY 3.

Warranted only to conform to the quantity and contents stated on the label or in the product labelling at the time of delivery to the customer. Immunostep disclaims hereby other warranties.

Immunostep's sole liability is limited to either the replacement of the products or refund of the purchase price.

## ADDITIONAL INFORMATION

For research use only. Not for diagnostic use.

Not for resale. Immunostep will not be responsible of violations that may occur with the use of this product. Any use of this product other than the specified in this document is strictly prohibited.


Unless otherwise indicated by Immunostep by written authorization, this product is intended for research only and is not to be used for any other purpose, including without limitation, for human or animal diagnostic, therapeutic or commercial purposes.

Please, refer to www.immunostep.com technical support for more information.

### 5. REFERENCES

- Favaloro EJ, Bradstock KF, Kabral A, Grimsley P, Zowtyj H, Zola H. Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging to CD-11b, CD-13 and CD-33. Br J Haematol1988 Jun;69(2):163-71.
- Favaloro EJ, Browning T, Facey D. CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated. Exp Hematol1993 Dec;21(13):1695-701.
- Favaloro EJ, Browning T, Nandurkar H. The hepatobiliary disease marker serum alanine aminopeptidase predominantly comprises an isoform of the haematological myeloid differentiation antigen and leukaemia marker CD-13/gp150. Clin Chim Acta1993 Oct 29;220(1):81-90.
- Riemann D. Kehlen A. Langner J. CD13--not just a marker in leukemia typing. Immunol Today1999 Feb;20(2):83-8.
- Mason D. Leucocyte typing VII: white cell differentiation antigens: proceedings of the Seventh International Workshop and Conference held in Harrogate, United Kindom. Oxford: Oxford University Press; 2002.
- Thalhammer-Scherrer R, Mitterbauer G, Simonitsch I, Jaeger U, Lechner K, Schneider B, et al. The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination. Am J Clin Pathol2002 Mar;117(3):380-9.

#### 6. **EXPLANATION OF SYMBOLS**



### MANUFACTURED BY:

7.



IMMUNOSTEP S.L.

Address: Avda. Universidad de Coimbra, s/n Cancer Research Center (C.I.C)

Campus de Unamuno 37007 Salamanca (Spain)

Telf./fax: (+34) 923 294 827 E-mail: info@immunostep.com

www.immunostep.com